|Videos|August 3, 2015
Will Biosimilars Impact the Cost of Specialty Drugs?
Author(s)Davy James, Managing Editor
Michael Zeglinski, Vice President of Specialty Pharmacy Operations at BriovaRx, discusses whether the R&D cost for biosimilars will affect the overall cost reduction.
Advertisement
Michael Zeglinski, Vice President of Specialty Pharmacy Operations at BriovaRx, discusses whether the R&D cost for biosimilars will affect the overall cost reduction.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
RSV Hospitalization Associated With Persistent Symptoms and Reduced Quality of Life in Adults
2
Study Links Specific Air Pollution Components to Increased Depression Risk in Older Adults
3
The Role of the Pharmacist in the Management of Psychosis in Parkinson’s Disease
4
December 2025 Product Updates
5